| CAS ID: | 989-51-5 |
| Molecular Formula: | C22H18O11 |
| Molecular Weight: | 458.4 g/mol |
| Monoisotopic Mass: | 458.0849 g/mol |
| Class: | Small Molecule |
| Natural Product: | Yes |
| Other Names: | (-)-Epigallocatechin Gallate |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1 | See All |
| InChI Key: | WMBWREPUVVBILR-WIYYLYMNSA-N | |
| Smiles: | Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c4cc(O)c(O)c(O)c4 | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 27935974 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,rat | Fibrosis Disease | Liver fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting miR-221 | ||
Reference Record 2
| PubMed ID | 27474435 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | EMT | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting TGF-β1 pathway, miR-21, miR-29a/b/c and miR-192 | ||
Reference Record 3
| PubMed ID | 23141425 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | |||
| Process II | fibroblasts proliferation | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting NF-κB signaling and CTGF | ||
Reference Record 4
| PubMed ID | 16841034 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Keloid |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 5
| PubMed ID | 22101032 | Target ID | |
| Uniprot ID | Name | ||
| Model | mice | Fibrosis Disease | Peritoneal fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00889434 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | April 28, 2009 | Last Verified | November 30, 2017 |
| Sponsor | Hadassah Medical Organization | ||
Trial Record 2
| ClinicalTrial ID | NCT00889434 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | April 28, 2009 | Last Verified | November 30, 2017 |
| Sponsor | Hadassah Medical Organization | ||
| PubChem: | 65064 |
| ChEMBL: | CHEMBL297453 |